Navigation Links
Wyeth Reports Earnings Results for the 2009 Second Quarter and First Half and Raises Full Year 2009 Guidance
Date:7/23/2009

s compared with the 2008 first half. The 2% increase, excluding the impact of foreign exchange, was primarily due to higher sales of Wyeth's key pharmaceutical franchises Prevnar,( )Enbrel (outside the U.S. and Canada) and Nutritional products, along with higher sales of Pristiq, the Protonix family, Tygacil( )and Torisel. These increases were partially offset by decreased sales of Effexor due primarily to increased generic competition in international markets and lower Enbrel alliance revenue. Excluding the impact of foreign exchange, net revenue for the 2009 first half for the Pharmaceuticals and Animal Health segments increased 2% and 6%, respectively, while Consumer Healthcare was comparable to the 2008 first half.

Gross margin, as a percentage of net revenue, excluding certain significant items, increased 1.2 percentage points to 74.3% for the 2009 first half from 73.1% for the 2008 first half. The increase was primarily due to the impact of foreign exchange rates and favorable manufacturing variances during the 2009 first half.

Selling, general and administrative expenses, excluding certain significant items, decreased 7% for the 2009 first half versus the 2008 first half and were comparable to the 2008 first half, excluding the impact of foreign exchange, as cost savings related to the Company's productivity initiatives were offset by increased pension expense.

Research and development expenses, excluding certain significant items, were comparable for the 2009 first half versus the 2008 first half and increased 2%, excluding the impact of foreign exchange. The increase, excluding the impact of foreign exchange, was primarily due to increased clinical trial spending, including oncology projects and Prevnar 13 adult.

Interest expense, net was $148.3 million for the 2009 first half as compared with interest income, net of $8.8 million for the 2008 first half. Thi
'/>"/>

SOURCE Wyeth
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine news :

1. Wyeth Announces Results of the Companys Offer Relating to Holder Right to Surrender Convertible Debentures
2. Wyeth Consumer Healthcare Announces the Availability of New Centrum Ultra Line of Multivitamins Specially Formulated For Women and Men
3. Wyeths Prevenar 13* Receives First Approval
4. Wyeth Pharmaceuticals and Catalyst Biosciences Announce Agreement to Develop and Commercialize Factor VIIa Products
5. Wyeth Files Definitive Proxy Statement and Announces Date for Annual Meeting of Stockholders
6. New Therapies, Including Novel Biologic Agents from Elan/Wyeth and Eli Lilly, Will Drive Robust 11 Percent Annual Growth In the Alzheimers Disease Market
7. Metastorm Customer, Wyeth Pharmaceuticals, Wins CIO 100 Award for BPM Project
8. DIA 45th Annual Meeting Features Sessions Highlighting Wyeth v. Levine and Pandemic Influenza
9. Wyeth Donates $100,000 to ASCO Cancer Foundation(R) to Support Cancer Prevention and Care
10. U.S. and 16 States Join Suits Against Pharmaceutical Giant, Wyeth
11. Wyeth Reports Earnings Results for the 2009 First Quarter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014 Truly hungry, or comforting yourself ... the TV, while driving, or at the computer can ... to be more aware of what they eat and ... Mindfulness” presentation. , Registered dietician and community educator ... questions from 12:30 to 2 p.m. Sept. 5 at ...
(Date:8/21/2014)... DMG Productions announces the upcoming airing of Innovations ... August 25, 2014 at 7:00 a.m. EST and 7:00 ... episode, Innovations will go behind-the-scenes to demonstrate how Freenotes ... Audiences will be amazed by the park's that focus ... providing access to real musical instruments. , Audiences will ...
(Date:8/21/2014)... San Luis Obispo, CA (PRWEB) August 21, 2014 ... July/August edition of Current Pedorthics, a bi-monthly publication of the ... the field of pedorthics. , Bunion Bootie ... as an alternative solution for bunion sufferers and their pain. ... be worn in nearly any shoe to eliminate the friction ...
(Date:8/21/2014)... Beverly Hills Medical Center of Kuwait is excited to ... a new diagnostic option for measuring tear production levels to ... TearLab is a revolutionary new testing method for dry ... amount of tears a patient produces and take the necessary ... Director at the Kuwait medical center. “The test collects a ...
(Date:8/21/2014)... Denver, CO (PRWEB) August 21, 2014 ... the first-ever Inspirational Sponsor for the American Lung Association ... , “We’re thrilled to welcome Webolutions as a sponsor,” ... of the Southwest, and Executive Director, American Lung Association ... bring to the table in this role they’ve defined.” ...
Breaking Medicine News(10 mins):Health News:HMHP Workshop to Focus on ‘Mindful’ Eating 2Health News:Announcing New Episode Airing of Innovations on Monday August 25, 2014 via Discovery Channel 2Health News:Recently Featured in Current Pedorthics: Bunion Bootie, the Very Popular Bunion Treatment Splint 2Health News:Recently Featured in Current Pedorthics: Bunion Bootie, the Very Popular Bunion Treatment Splint 3Health News:Beverly Hills Kuwait is the First Medical Center in Kuwait with Access to TearLab 2Health News:Denver Marketing Agency Webolutions Named Inspirational Sponsor for 2014 Run the ‘Rocks 5K 2Health News:Denver Marketing Agency Webolutions Named Inspirational Sponsor for 2014 Run the ‘Rocks 5K 3
... Revenue Up 16% ... Cellulite Product Launch Targeted for Late Q1 ... Company Updates Guidance for Full Year 2007, HAYWARD, Calif., Nov. 6 ... the aesthetic,industry, today reported its financial results for the third quarter ended,September 30, ...
... Organizations Rapidly Identify High-Risk Cases, Provide ... BIRMINGHAM, Ala., Nov. 6 The ... DST Health Solutions announced that 16,organizations have ... helps organizations rapidly identify at-risk patients for,care ...
... - Continued progress in both core business segments supports ... Corporation,(Nasdaq: VRNM ), a leading developer of technologies ... of high-performance specialty,enzymes, today reported financial results for the ... "We are very pleased with the progress the Company ...
... Mass., Nov. 6 Biopure Corporation,(Nasdaq: BPUR ... public,offering of stock and warrants that raised net ... exercise of the warrants. Biopure,sold 19,377,500 new shares ... an,additional 19,377,500 shares, including 2,527,500 shares and 2,527,500,warrants ...
... group says , TUESDAY, Nov. 6 (HealthDay News) -- Standard ... been proposed by a team of Johns Hopkins experts, who ... comparisons and help improve patient safety. , "Hospitals are ... this is long overdue, the data is only helpful if ...
... for patients with sudden, life-threatening attacks, trial shows , , ... kind of medication has failed as treatment for the ... trial finds. , The drug, tezosentan, did not improve ... or cut their risk of death after acute ...
Cached Medicine News:Health News:Thermage Announces Third Quarter Financial Results 2Health News:Thermage Announces Third Quarter Financial Results 3Health News:Thermage Announces Third Quarter Financial Results 4Health News:Thermage Announces Third Quarter Financial Results 5Health News:Thermage Announces Third Quarter Financial Results 6Health News:Thermage Announces Third Quarter Financial Results 7Health News:Thermage Announces Third Quarter Financial Results 8Health News:Thermage Announces Third Quarter Financial Results 9Health News:Sixteen Organizations Implement ACG Rx-PM Predictive Modeling from Johns Hopkins University, DST Health Solutions 2Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 2Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 3Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 4Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 5Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 6Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 7Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 8Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 9Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 10Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 11Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 12Health News:Experimental Drug Fails Against Heart Failure 2Health News:Experimental Drug Fails Against Heart Failure 3
(Date:8/20/2014)... 2014 Reportlinker.com announces that a ... its catalogue: Personal Accident and ... Opportunities to 2017 ... report provides in depth market analysis, information ... and health insurance segment, including: • The ...
(Date:8/20/2014)... -- The National Necrotizing Fasciitis Foundation (NNFF) today announced that ... treated for a life threatening form of necrotizing fasciitis, or ... Medical Director of Inpatient Wound Care and founder of The ... Rancho Mirage, California . Dr. Gauto ... at Seton Hospital in Daly City, California ...
(Date:8/20/2014)...   Ventana Medical Systems, Inc.  (Ventana), a ... its VENTANA System for Primary Diagnosis 1 ... for routine pathology, including primary diagnosis with human ... software coupled with either the VENTANA iScan Coreo ... automated digital slide creation, case management and computer ...
Breaking Medicine Technology:Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 2Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 3Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 4Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 5Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 6Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 7Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 8Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 9Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 10Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 11Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 12Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 13Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 14Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 15Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 16Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 17Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 18Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 19Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 20Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 21Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 22Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 23Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 2Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 3Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 4Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 5Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 6Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 2Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 3
... 13, 2007--Active Biotech AB,(Stockholm:ACTI.ST) and Chelsea Therapeutics ... micro-dosing trial of an,I-3D compound. , The ... the pharmacokinetic,characteristics of the compound in humans. ... The study demonstrated that the selected I-3D ...
... 2007 /PRNewswire-FirstCall/ -- CV,Therapeutics, Inc. announced today that ... data from the Ranolazine Open Label,Experience (ROLE) program, ... to be safe and well,tolerated in patients with ... 3 clinical trials, and enrolled in the ROLE,program. ...
Cached Medicine Technology:Active Biotech's I-3D Micro-dosing Clinical Trial Concluded 2JACC Publishes Long-Term Safety and Tolerability Data from,Ranolazine Open Label Experience (ROLE) Program 2JACC Publishes Long-Term Safety and Tolerability Data from,Ranolazine Open Label Experience (ROLE) Program 3JACC Publishes Long-Term Safety and Tolerability Data from,Ranolazine Open Label Experience (ROLE) Program 4
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
Medicine Products: